How does the color of a pill affect its efficacy?

Nov 15, 2010

According to recent research the color, shape, taste and even name of a tablet or pill can have an effect on how patients feel about their medication. Choose an appropriate combination and the placebo effect gives the pill a boost, improves outcomes and might even reduce side effects. Now, researchers at the University of Bombay, New Mumbai, India, have surveyed users of over-the-counter (OTC) medication to find out just how much the color of a tablet influences patient choice.

Writing in the International Journal of Biotechnology, R.K. Srivastava and colleagues report that red and pink tablets are preferred over other colors. Their survey of 600 people showed that for three quarters of people the color and shape of their tablets act as a memory tag for compliance. Strangely, they found that 14 percent of people think of pink tablets as tasting sweeter than red tablets whereas a yellow tablet is perceived as salty irrespective of its actual ingredients. 11% thought of white or blue tablets as tasting bitter and 10% said orange-colored tablets were sour.

Twice as many middle-aged people preferred red tablets as younger adults and more women chose red tablets as were chosen by men. Color seems to be integral component of an OTC product, the team says.

Patients may trust their doctor or , but this does not mean they will take the bitterest pill. "Patients undergo a sensory experience every time they self-administer a drug, whether it's swallowing a tablet or capsule, chewing a tablet, swallowing a liquid, or applying a cream or ointment," the team says. "The ritual involving perceptions can powerfully affect a patient's view of treatment effectiveness." The researchers suggest that it might be possible to ensure that all the sensory elements of given medication work together to create positive perceptions that complement the attributes. They point out, however, that surprisingly little attention has been paid to this aspect of pharmaceutical formulation.

The research has implications for marketing OTC medication to different age groups and to men and women. However, given that compliance in taking medication strongly depends on the patient's of that medication the study could also have important connotations for improving effects. If patients are disinclined to take a tablet they consider bitter or sour or because they simply do not like the , then a change of aesthetics might be needed. The same research might apply equally to prescription medicines.

Explore further: FDA approves new drug for rare genetic disease

More information: "Some aesthetic considerations for over the-counter (OTC) pharmaceutical products" in Int. J. Biotechnol., 2010, 11, 267-283

add to favorites email to friend print save as pdf

Related Stories

FDA OKs 50th & 51st anti-retroviral drugs

Aug 14, 2007

The U.S. Food and Drug Administration has tentatively approved nevirapine tablets and a pediatric medication used to treat the human immunodeficiency virus.

New pill to treat multiple sclerosis

Apr 30, 2009

A new drug for multiple sclerosis can dramatically reduce the chances of a relapse or a deterioration of the condition, according to a new study from researchers at Queen Mary, University of London.

FDA issues Myfortic tablets safety alert

Nov 28, 2007

The U.S. Food and Drug Administration issued a safety alert for pregnant patients using the kidney transplant drug Myfortic delayed-release tablets.

Recommended for you

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments : 0